Harvest Integrated Research Organization(HiRO) is a global clinical research organization (CRO) that specializes in cross-border clinical trial solutions. The organization has recently issued a statement announcing that they have signed a Memorandum of Understanding (MOU) with CHA University Bundang Medical Center(CMBC) in Seoul, South Korea.
Under this strategic partnership, HiRO and CBMC will cooperate closely to deliver all-rounded clinical trial solutions for biotechnology and pharmaceutical companies around the world in terms of providing clinical trial solutions for the entire phase from Phase I to Phase IV. Under this cooperative work, the organizations will together focus on optimizing processes in conducting clinical trials while encouraging innovation for improved healthcare research in both South Korea and the globe.
As a flagship hospital of the CHA Medical Group, one of South Korea's largest biomedical groups, CBMC is distinguished for its state-of-the-art medical services and robust research capabilities. CBMC's collaboration with HiRO will focus on providing valuable insights and support for clinical trials conducted at the center, spanning critical areas such as feasibility assessments, principal investigator selection, and the facilitation of patient recruitment processes. Correspondingly, HiRO will actively showcase the clinical research capabilities of South Korea and CBMC on global platforms, highlighting the exceptional facilities, skilled professionals, and research excellence of the region and the center.
Dr. Young-Sang Kim, Director of CHA Global Clinical Trials Center, underscored the significance of the collaboration, expressing, "Through our partnership with HiRO, we are poised to elevate our clinical research expertise and medical excellence. Drawing on HiRO's presence across the US, Europe, and the Asia-Pacific region, we are reinforcing our commitment to providing more effective and pioneering treatments on a global scale, ultimately improving outcomes for patients in need".
Dr. Karen Chu, Founder and CEO of HiRO, echoed this sentiment, expressing excitement about the partnership. She stated, "South Korea is a prime destination for clinical trials, with a robust healthcare infrastructure and favorable research environment. Our collaboration with CBMC represents a strategic alignment of our missions to provide top-notch services to our global clients and drive their innovation forward. We are confident that this partnership will further enhance our ability to offer capital-efficient and high-quality clinical trial solutions, leading to impactful results and significant advancements in medical breakthroughs".
Both organizations are enthusiastic about the prospects of their collaboration and are committed to exploring innovative avenues together. The signing of the MOU between HiRO and CHA Bundang Medical Center marks the beginning of a promising partnership to shape the future of clinical research in South Korea and beyond.
